IOL Chemicals and Pharmaceuticals Limited — PPTs, 07-08-2025: Investor Presentation

**1. Financial Highlights:**

IOLCP's Q1 FY26 financial results show Revenue from Operations reached ₹551.7 Cr (+9.8% YoY) and Profit After Tax (PAT) hit ₹34.0 Cr (+14.4% YoY). The company reported an EBITDA margin of 12.4%, PAT margin of 6.1%, and a healthy 0.07 Debt to Equity Ratio.

**2. Strategic Initiatives & Growth Drivers:**

A key strategic shift involves expanding the non-Ibuprofen pharma portfolio, now contributing 34% of segment revenue. A new ₹5.5 Cr Minoxidil facility (120 MTPA) is planned by Dec 2025. IOLCP acquired 101 acres for future expansion and aims to boost export revenue to ~40% through regulatory filings. Backward integration enhances cost efficiency.

**3. Business Developments:**

IOLCP obtained REACH registration for Acetic Anhydride, enabling EU exports, and earned an EcoVadis Silver Medal for strong sustainability performance.

**4. Market Position & Competitive Advantage:**

Global leader in Ibuprofen (~30% market share) with unique full backward integration. Also a top producer of Iso Butyl Benzene. Extensive regulatory filings (16 DMFs, 19 CEPs) and a robust R&D pipeline reinforce its strong market position.

**5. Investor Implications:**

These updates suggest positive growth potential from product diversification, capacity expansion, and improved global market access. Investors should monitor project execution.